← Back to Search

Psychedelic

DMT for Depression

Phase 1
Waitlist Available
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up -60 minutes before dmt administration; 0, +30, and +60 minutes after dmt administration
Awards & highlights

Study Summary

This trial is testing the safety and effectiveness of DMT, a psychedelic drug, in humans.

Who is the study for?
This trial is for people who are mentally and physically healthy, without any major depressive disorder or other psychiatric conditions. It's designed to see if DMT can be safe and effective for those not currently experiencing depression.Check my eligibility
What is being tested?
The study is testing two different doses of Dimethyltryptamine (DMT), a psychedelic compound: one lower dose at 0.1 mg/kg and a higher dose at 0.3 mg/kg, to understand its effects on humans in a controlled setting.See study design
What are the potential side effects?
Possible side effects of DMT may include altered sense of time, visual hallucinations, euphoria, increased heart rate, rapid eye movement, dizziness, and anxiety during the period it's active in the body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~-60 minutes before dmt administration; 0, +30, and +60 minutes after dmt administration
This trial's timeline: 3 weeks for screening, Varies for treatment, and -60 minutes before dmt administration; 0, +30, and +60 minutes after dmt administration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Anxiety
Change in Blood Pressure
Change in Heart Rate
+3 more

Trial Design

2Treatment groups
Active Control
Group I: 0.1 mg/kg DMTActive Control1 Intervention
0.1 mg/kg DMT administered intravenously
Group II: 0.3 mg/kg DMTActive Control1 Intervention
0.3 mg/kg DMT administered intravenously

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,863 Previous Clinical Trials
2,742,551 Total Patients Enrolled
63 Trials studying Depression
20,616 Patients Enrolled for Depression

Media Library

Dimethyltryptamine (DMT) (Psychedelic) Clinical Trial Eligibility Overview. Trial Name: NCT04711915 — Phase 1
Depression Research Study Groups: 0.1 mg/kg DMT, 0.3 mg/kg DMT
Depression Clinical Trial 2023: Dimethyltryptamine (DMT) Highlights & Side Effects. Trial Name: NCT04711915 — Phase 1
Dimethyltryptamine (DMT) (Psychedelic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04711915 — Phase 1
~4 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top